Literature DB >> 11862497

Nausea and emesis: still an unsolved problem in cancer patients?

Jørn Herrstedt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11862497     DOI： 10.1007/s00520-001-0339-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  21 in total

1.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

Authors:  R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

2.  ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV).

Authors: 
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

3.  Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

Authors:  D Campos; J R Pereira; R R Reinhardt; C Carracedo; S Poli; C Vogel; J Martinez-Cedillo; A Erazo; J Wittreich; L O Eriksson; A D Carides; B J Gertz
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

4.  Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients.

Authors:  A Molassiotis; B M C Yam; H Yung; F Y S Chan; T S K Mok
Journal:  Support Care Cancer       Date:  2001-11-20       Impact factor: 3.603

Review 5.  Delayed emesis: incidence, pattern, prognostic factors and optimal treatment.

Authors:  Fausto Roila; Donatella Donati; Stefano Tamberi; Guido Margutti
Journal:  Support Care Cancer       Date:  2001-08-23       Impact factor: 3.603

Review 6.  Nausea and emesis: evidence for a biobehavioral perspective.

Authors:  Gary R Morrow; Joseph A Roscoe; Jane T Hickok; Paul R Andrews; Sara Matteson
Journal:  Support Care Cancer       Date:  2001-08-10       Impact factor: 3.603

7.  The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.

Authors:  B Lebeau; A Depierre; M Giovannini; A Rivière; L Kaluzinski; B Votan; M Hédouin; H d'Allens
Journal:  Ann Oncol       Date:  1997-09       Impact factor: 32.976

8.  Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  D Osoba; B Zee; J Pater; D Warr; J Latreille; L Kaizer
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

9.  Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.

Authors:  R de Wit; H van den Berg; J Burghouts; J Nortier; P Slee; C Rodenburg; J Keizer; M Fonteyn; J Verweij; J Wils
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

10.  Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.

Authors:  C W Lee; C W Suh; J S Lee; K H Lee; G Y Cho; S W Kim; S H Kim
Journal:  J Korean Med Sci       Date:  1994-10       Impact factor: 2.153
View more
  6 in total

1.  Cost-utility analysis of aprepitant for patients who truly need it in Japan.

Authors:  Ikuto Tsukiyama; Masahiko Ando; Sumiyo Tsukiyama; Masayuki Takeuchi; Masayuki Ejiri; Yusuke Kurose; Hiroko Saito; Ichiro Arakawa; Tadao Inoue; Etsuro Yamaguchi; Akihito Kubo
Journal:  Support Care Cancer       Date:  2019-02-01       Impact factor: 3.603

2.  Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.

Authors:  Nibal Abunahlah; Mesut Sancar; Faysal Dane; Mustafa Kerem Özyavuz
Journal:  Int J Clin Pharm       Date:  2016-10-28

3.  End-of-life care of women with gynecologic malignancies: a pilot study.

Authors:  Nicole S Nevadunsky; Lori Spoozak; Sharon Gordon; Enid Rivera; Kimala Harris; Gary L Goldberg
Journal:  Int J Gynecol Cancer       Date:  2013-03       Impact factor: 3.437

4.  Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Authors:  Nabil Adra; Costantine Albany; Mary J Brames; Somer Case-Eads; Cynthia S Johnson; Ziyue Liu; Christopher A Fausel; Timothy Breen; Nasser H Hanna; Ralph J Hauke; Joel Picus; Lawrence H Einhorn
Journal:  Support Care Cancer       Date:  2016-02-02       Impact factor: 3.603

5.  Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.

Authors:  Mototsugu Shimokawa; Toshinobu Hayashi; Junichi Nishimura; Taroh Satoh; Mutsumi Fukunaga; Reiko Matsui; Yasushi Tsuji; Fumitaka Mizuki; Takahiro Kogawa
Journal:  BMC Cancer       Date:  2021-10-16       Impact factor: 4.430

6.  Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy.

Authors:  Ikuto Tsukiyama; Shiori Hasegawa; Yoshiaki Ikeda; Masayuki Takeuchi; Sumiyo Tsukiyama; Yusuke Kurose; Masayuki Ejiri; Masaki Sakuma; Hiroko Saito; Ichiro Arakawa; Tadao Inoue; Etsuro Yamaguchi; Akihito Kubo
Journal:  Cancer Sci       Date:  2018-08-03       Impact factor: 6.716
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.